Advertisement
ANGO vs BNR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANGO is a Hold and BNR is a Hold.
ANGO in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 06, 2026
ANGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where ANGO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANGO's RSI Oscillator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where ANGO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ANGO as a result. In 67 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in 197 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
ANGO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ANGO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for ANGO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.908) is normal, around the industry mean (4.961). P/E Ratio (-13.659) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.005) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ANGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Momentum Indicator for BNR turns negative, indicating new downward trend
BNR saw its Momentum Indicator move below the 0 level on October 08, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 79 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BNR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 21 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Moving Average Convergence Divergence Histogram (MACD) for BNR turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 61 cases where BNR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
BNR moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNR advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BNR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 88 of 111 cases where BNR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. BNR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (66.046). P/E Ratio (-1.142) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.741) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
ANGO | BNR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 95 | |
PRICE GROWTH RATING 1..100 | 63 | 44 | |
P/E GROWTH RATING 1..100 | 27 | 77 | |
SEASONALITY SCORE 1..100 | n/a | 37 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANGO's Valuation (18) in the Medical Specialties industry is in the same range as BNR (49) in the null industry. This means that ANGO’s stock grew similarly to BNR’s over the last 12 months.
ANGO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BNR (100) in the null industry. This means that ANGO’s stock grew similarly to BNR’s over the last 12 months.
BNR's SMR Rating (95) in the null industry is in the same range as ANGO (96) in the Medical Specialties industry. This means that BNR’s stock grew similarly to ANGO’s over the last 12 months.
BNR's Price Growth Rating (44) in the null industry is in the same range as ANGO (63) in the Medical Specialties industry. This means that BNR’s stock grew similarly to ANGO’s over the last 12 months.
ANGO's P/E Growth Rating (27) in the Medical Specialties industry is somewhat better than the same rating for BNR (77) in the null industry. This means that ANGO’s stock grew somewhat faster than BNR’s over the last 12 months.
| ANGO | BNR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| MACD ODDS (%) | N/A | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 75% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 73% | 2 days ago 82% |
| Declines ODDS (%) | 10 days ago 72% | 4 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 72% |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANGO’s FA Score shows that 2 FA rating(s) are green while BNR’s FA Score has 0 green FA rating(s).
- ANGO’s FA Score: 2 green, 3 red.
- BNR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANGO’s TA Score shows that 5 TA indicator(s) are bullish while BNR’s TA Score has 5 bullish TA indicator(s).
- ANGO’s TA Score: 5 bullish, 4 bearish.
- BNR’s TA Score: 5 bullish, 4 bearish.
Price Growth
ANGO (@Pharmaceuticals: Other) experienced а +3.80% price change this week, while BNR (@Medical Specialties) price change was -7.53% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.59%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was +7.47%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
Reported Earning Dates
ANGO is expected to report earnings on Jan 07, 2027.
BNR is expected to report earnings on Nov 19, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.59% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BNR and
Correlation & Price change
A.I.dvisor tells us that BNR and RVTY have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNR and RVTY's prices will move in lockstep.
| Ticker / NAME | Correlation To BNR | 1D Price Change % | ||
|---|---|---|---|---|
| BNR | 100% | -1.92% | ||
| RVTY - BNR | 25% Poorly correlated | +0.48% | ||
| ACRS - BNR | 24% Poorly correlated | +0.52% | ||
| STXS - BNR | 24% Poorly correlated | +0.31% | ||
| ANGO - BNR | 23% Poorly correlated | +1.09% | ||
| GKOS - BNR | 23% Poorly correlated | -0.09% | ||
More | ||||